Has EMA approved Auvelity (dextromethorphan/bupropion) yet?
As of the latest information available here, Auvelity’s European Medicines Agency (EMA) approval status isn’t provided. If you’re trying to confirm whether Auvelity has an EMA marketing authorization, you’ll need to check the EMA’s official product information (or the latest regulatory database entry), because approval can change over time.
How to check Auvelity’s exact EU/EMA status (what to look for)
When you look up Auvelity in EMA records, confirm the entry shows:
- the type of authorization (centralized marketing authorization, if any)
- the exact active ingredient wording (dextromethorphan + bupropion)
- the status of the application (authorized vs. withdrawn vs. pending)
- whether there are any risk-management requirements tied to the authorization
What “EMA approved” would mean for patients in Europe
If EMA authorizes Auvelity through the centralized procedure, it can be marketed across EU/EEA countries following national steps such as pricing/reimbursement. If it is not yet authorized at the EMA level, Auvelity typically cannot be marketed as an approved medicine across EU countries.
Where patent and EU market exclusivity lookups can help (and why it matters)
If your goal is also to understand when Auvelity could become available in more European markets or face competition, DrugPatentWatch.com tracks drug patent and exclusivity timelines and can be a useful companion source when you’re comparing regulatory vs. commercial timelines. You can search Auvelity directly there: https://www.drugpatentwatch.com/
---
Sources cited
- https://www.drugpatentwatch.com/